肾癌诊断后戒烟与死亡和癌症进展风险降低相关:一项前瞻性队列研究
该前瞻性队列研究纳入212例原发肾细胞癌患者,2007至2016年招募,随访至2020年,中位随访8.2年。诊断后戒烟与全因死亡(HR 0.51)、疾病进展(HR 0.45)和癌症特异性死亡(HR 0.54)风险降低相关,各亚组均可见获益。
要点
- 肾癌诊断后戒烟与全因死亡风险降低相关(HR 0.51;95%CI 0.31-0.85)。
- 戒烟与疾病进展风险降低相关(HR 0.45;95%CI 0.29-0.71)。
- 戒烟与癌症特异性死亡风险降低相关(HR 0.54;95%CI 0.31-0.93)。
核心结论
- 肾细胞癌诊断后戒烟可能显著改善吸烟患者的生存并降低疾病进展和癌症死亡风险。
研究设计与样本
- 前瞻性队列研究,2007至2016年从俄罗斯莫斯科N.N. Blokhin国家肿瘤医学研究中心泌尿科招募212例原发肾细胞癌患者,入组时完成结构化问卷,每年随访至2020年重复评估吸烟状态和疾病进展。
主要发现
- 中位随访8.2年,期间记录110例疾病进展、100例总死亡和77例癌症特异性死亡。
- 84例患者(40%)在诊断后戒烟。
- 继续吸烟期和戒烟期的总风险人年分别为748.2和611.2。
- 随访5年时,戒烟期较继续吸烟期的总生存率(85% vs 61%)和无进展生存率(80% vs 57%)均更高(均P < .001)。
- 多变量时间依赖模型中,戒烟与较低的全因死亡风险(HR 0.51;95%CI 0.31-0.85)、疾病进展风险(HR 0.45;95%CI 0.29-0.71)和癌症特异性死亡风险(HR 0.54;95%CI 0.31-0.93)相关。
关键数值与推荐
- 戒烟期较继续吸烟期5年总生存率85% vs 61%(P < .001)。
- 戒烟期较继续吸烟期5年无进展生存率80% vs 57%(P < .001)。
- 戒烟与全因死亡风险HR 0.51(95%CI 0.31-0.85)。
- 戒烟与疾病进展风险HR 0.45(95%CI 0.29-0.71)。
- 戒烟与癌症特异性死亡风险HR 0.54(95%CI 0.31-0.93)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate whether postdiagnosis smoking cessation may affect the risk of death and disease progression in patients with renal cell carcinoma (RCC) who smoked at the time of diagnosis. METHODS: Two hundred twelve patients with primary RCC were recruited between 2007 and 2016 from the Urological Department in N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia. Upon enrollment, a structured questionnaire was completed, and the patients were followed annually through 2020 to repeatedly assess their smoking status and disease progression. Survival probabilities and hazards for all-cause and cancer-specific mortality and disease progression were investigated using extended the Kaplan-Meier method, time-dependent Cox proportional hazards regression, and Fine-Gray competing-risk models. RESULTS: Patients were followed for a median of 8.2 years. During this time, 110 cases of disease progression, 100 total deaths, and 77 cancer-specific deaths were recorded. Eighty-four patients (40%) quit smoking after diagnosis. The total person-years at risk for this analysis were 748.2 for continuing smoking and 611.2 for quitting smoking periods. At 5 years of follow-up, both overall survival (85% v 61%) and progression-free survival (80% v 57%) rates were higher during the quitting than continuing smoking periods (both P < .001). In the multivariable time-dependent models, quitting smoking was associated with lower risk of all-cause mortality (hazard ratio [HR], 0.51; 95% CI, 0.31 to 0.85), disease progression (HR, 0.45; 95% CI, 0.29 to 0.71), and cancer-specific mortality (HR, 0.54; 95% CI, 0.31 to 0.93). The beneficial effect of quitting smoking was evident across all subgroups, including light smokers versus moderate-heavy smokers and those with early-stage versus late-stage tumors. CONCLUSION: Quitting smoking after RCC diagnosis may significantly improve survival and reduce the risk of disease progression and cancer mortality among patients who smoke.
引用
- Sheikh M, Mukeriya A, Zahed H, et al. Smoking Cessation After Diagnosis of Kidney Cancer Is Associated With Reduced Risk of Mortality and Cancer Progression: A Prospective Cohort Study. J Clin Oncol. 2023. PMID: 36989465. doi:10.1200/JCO.22.02472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。